Press release
Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market
The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020-2034.The Lipodystrophy market report [https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Lipodystrophy market size, share, Lipodystrophy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Lipodystrophy market size growth forward.
Some of the key highlights from the Lipodystrophy Market Insights Report:
*
Several key pharmaceutical companies, including Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others, are developing novel products to improve the Lipodystrophy treatment outlook.
*
In November 2024, Amryt Pharma initiated an open-label extension of the APG-20 study to assess the long-term safety and efficacy of daily subcutaneous metreleptin treatment in individuals with partial lipodystrophy. This Phase 3 study aims to continue evaluating metreleptin's long-term impact on this patient population.
*
Lipodystrophy is a rare condition characterized by abnormal fat distribution in the body, which can lead to either fat loss (lipoatrophy) or fat accumulation in unusual areas (lipohypertrophy). According to DelveInsight's 2023 estimates, there were around 3,077 prevalent cases of lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.
*
In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, which predominantly affects females. This is primarily due to familial partial lipodystrophy (FPL), a common type linked to genetic mutations in the LMNA or PPARG genes, which are more frequent in women. Additionally, around 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy, a condition marked by near-total fat loss, resulting in visible muscle mass, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).
*
The US FDA has approved two therapies for lipodystrophy: MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin), produced by Amryt Pharma and Thera Technologies, respectively. The pipeline for lipodystrophy treatment is limited, with only a few companies advancing their candidates through clinical trials. Notable candidates include REGN4461 by Regeneron Pharmaceuticals, which is currently in Phase II. The rarity of the condition poses challenges for patient recruitment in clinical trials, slowing the development of new treatments.
*
The US holds the largest share of the lipodystrophy market, driven by the high prevalence of the condition and the availability of approved treatments. MYALEPT (metreleptin) by Amryt Pharma plays a significant role, with its leptin-based therapy generating substantial revenue.
*
As per DelveInsight analysis, the Lipodystrophy market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Lipodystrophy Market Landscape [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lipodystrophy Overview
Lipodystrophy is a rare condition characterized by abnormal fat distribution, either through fat loss (lipoatrophy) or fat buildup (lipohypertrophy). It can either be congenital (inherited) or develop later in life. This disorder often results in significant metabolic issues. Congenital forms include congenital generalized lipodystrophy (CGL), which causes extensive fat loss and metabolic problems like insulin resistance, and familial partial lipodystrophy (FPL), where fat is lost in certain areas and accumulates in others. Acquired lipodystrophy may develop later in life, sometimes linked to autoimmune diseases. Acquired generalized lipodystrophy (AGL) causes widespread fat loss, while acquired partial lipodystrophy (APL) leads to progressive fat loss in the upper body with accumulation in the lower body. HIV-associated lipodystrophy can occur as a side effect of antiretroviral treatment.
Symptoms of lipodystrophy include fat loss in areas like the face, arms, legs, and buttocks, abnormal fat buildup in the neck and trunk, and metabolic problems such as insulin resistance and diabetes.
Diagnosis typically involves a clinical assessment, metabolic tests, imaging techniques such as MRI or CT scans, and, in some cases, genetic testing or fat biopsies.
Do you know the treatment paradigms for different countries? Download our Lipodystrophy Market Sample Report [https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lipodystrophy Epidemiology Insights
*
DelveInsight's 2023 estimates suggest that there were around 3,077 prevalent cases of the rare disease lipodystrophy across the 7MM, with the United States representing 35% of these cases.
Lipodystrophy Epidemiology Segmentation
DelveInsight's Lipodystrophy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Lipodystrophy historical patient pools and forecasted Lipodystrophy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Lipodystrophy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
*
Lipodystrophy Prevalence
*
Age-Specific Lipodystrophy Prevalence
*
Gender-Specific Lipodystrophy Prevalence
*
Diagnosed and Treatable Cases of Lipodystrophy
Visit for more @ Lipodystrophy Epidemiological Insights [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lipodystrophy Market Insights:
*
The US holds the largest share of the lipodystrophy market, due to the high prevalence of the condition and the presence of approved treatments. MYALEPT (metreleptin) by Amryt Pharma is a major contributor, with its leptin-based therapy generating significant revenue, around $880,000.
Lipodystrophy Market Outlook
The lipodystrophy treatment market is progressing, highlighting both existing and new therapies. In the United States, leading approved treatments such as MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin) dominate the market, generating significant revenue.
Lipodystrophy Marketed Drugs
*
MYALEPT (metreleptin): Amryt Pharma
*
EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies
Lipodystrophy Emerging Drugs
*
REGN4461: Regeneron Pharmaceuticals
*
Subcutaneous Metreleptin: Amryt Pharma
Lipodystrophy Key Companies
*
Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others
For more information, visit Lipodystrophy Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Scope of the Lipodystrophy Market Report:
*
11 Years Forecast
*
7MM Coverage
*
Descriptive overview of Lipodystrophy, causes, signs and symptoms, diagnosis, treatment
*
Comprehensive insight into Lipodystrophy epidemiology in the 7MM
*
Lipodystrophy marketed and emerging therapies
*
Lipodystrophy companies
*
Lipodystrophy market drivers and barriers
Table of Contents:
1 Lipodystrophy Market Key Comprehensive Insights
2 Lipodystrophy Market Report Introduction
3 Competitive Intelligence Analysis for Lipodystrophy
4 Lipodystrophy Market Analysis Overview at a Glance
5 Executive Summary of Lipodystrophy
6 Lipodystrophy Epidemiology and Market Methodology
7 Lipodystrophy Epidemiology and Patient Population
8 Lipodystrophy Patient Journey
9 Lipodystrophy Treatment Algorithm, Lipodystrophy Current Treatment, and Medical Practices
10 Key Endpoints in Lipodystrophy Clinical Trials
11 Lipodystrophy Marketed Therapies
12 Lipodystrophy Emerging Therapies
13 Lipodystrophy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Lipodystrophy
16 Lipodystrophy Market Key Opinion Leaders Reviews
18 Lipodystrophy Market Drivers
19 Lipodystrophy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Lipodystrophy Epidemiology 2034
DelveInsight's "Lipodystrophy - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Lipodystrophy Pipeline 2024
"Lipodystrophy Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lipodystrophy market. A detailed picture of the Lipodystrophy pipeline landscape is provided, which includes the disease overview and Lipodystrophy treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lipodystrophy-market-expected-to-rise-2034-ionis-pharmaceuticals-regeneron-pharmaceuticals-boehringer-ingelheim-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market here
News-ID: 3851689 • Views: …
More Releases from ABNewswire

Stellar Scientific Explains Why Gravity Convection Ovens Are Perfect for Delicat …
Stellar Scientific explains how gravity convection ovens ensure consistent and delicate heating, making them perfect for precision cooking in various industries.
In laboratory and industrial environments, precision and consistency are crucial when it comes to heating applications. Whether it's for drying, sterilizing, or sample preparation, a stable and uniform heat distribution ensures accurate results. Gravity convection ovens, known for their reliability and delicate temperature control, are an ideal solution for such…

Unlocking Potential with ABA Therapy: How A Gem of Joy ABA Helps Children with A …
A Gem of Joy ABA in Baltimore, MD, uses ABA therapy to unlock potential in children with autism, helping them develop key skills for a brighter future.
Baltimore, MD - Autism Spectrum Disorder (ASD) affects millions of children worldwide, presenting unique challenges in communication, behavior, and social interaction. For families in Baltimore, MD, finding effective therapies is essential in helping children with autism reach their full potential. A Gem of Joy…

The Healing Power of Art: How Creative Therapy Zone in Thornhill, ON, Uses Art T …
Creative Therapy Zone in Thornhill, ON, harnesses the healing power of art therapy, helping individuals improve mental wellness through creative expression and support.
Thornhill, ON - Mental wellness is an essential aspect of overall health, and individuals facing mental health challenges often seek therapeutic approaches that go beyond traditional talk therapy. Art therapy has emerged as a powerful tool for individuals looking to express themselves, process emotions, and heal through creativity.…

Stellar Scientific Launches WiFi-Controlled Peristaltic Pumps, Eliminating Conta …
Stellar Scientific introduces WiFi-controlled peristaltic pumps, offering precision and eliminating contamination risk in critical research applications for greater accuracy.
Owings Mills, MD - July 25, 2025 - Stellar Scientific, a leading provider of laboratory equipment and supplies for life science research, today announced US distribution of Microlit's revolutionary WiFi-enabled peristaltic pumps [https://www.stellarscientific.com/peristaltic-pumps/]-the industry's first wireless-controlled fluid handling systems. These breakthrough pumps directly address the $2.8 billion annual cost of laboratory contamination…
More Releases for Lipodystrophy
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline…
HIV-Associated Lipodystrophy Treatment Market 2024-2031 | Exclusive Study Report
HIV-Associated Lipodystrophy Treatment Market worth $239.62 Mn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global HIV-Associated Lipodystrophy Treatment Market - (by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)), Trends, Industry Competition Analysis,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot
HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology…
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The…
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,…